Analysts have given recommendations for companies including Dr Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Laurus Labs Ltd., Hindustan Construction Co. and IPCA Laboratories Ltd.

As per the stock calls shared with NDTV Profit, some of these companies could see upside of as much as 9% in the near term from current levels. Some of them have already yielded as much as nearly 54% in the past 12 months.

Here are the top stocks to buy, as per Vaishali Parekh, vice president of technical research at Prabhudas Lilladher; Ajit Mishra, senior vice president of research at Religare Broking; Vinay Rajani, senior technical and derivative research analyst at HDFC Securities; and Sudeep Shah, deputy Vice President of technical and derivatives research at SBICAP Securities.

Dr Reddy’s Laboratories 

Parekh recommends buying the stock at Rs 1,385 with a target price of Rs 1,450 and a stop loss at Rs 1,340. Over the past 12 months, the stock has gained 19.33%, while its year-to-date performance stands at 19.82%. Relative strength index for the counter stands at 75.60, showing that it is overbought.

According to Bloomberg, 40 analysts track the stock: 14 rate it a ‘buy,’ 12 a ‘hold,’ and 14 a ‘sell.’ The consensus 12-month target price is Rs 1375.35, indicating a potential downside of 2.3%.

Aurobindo Pharma

According to Mishra, the stock is a ‘buy’ at Rs 1,270, with a target price of Rs 1,350 and a stop loss at Rs 1,230. It has gained 17.57% in the last 12 months and 17.15% year-to-date. The stock’s relative strength index stands at 52.09.

Bloomberg shows that 29 analysts cover the stock: 20 rate it ‘buy,’ five suggest ‘hold,’ and four recommend ‘sell.’ The consensus 12-month target price of Rs 1,530 implies a potential upside of 20.5%.

Laurus Labs

Shah has suggested buying this stock at Rs 586 with a target price of Rs 625 and a stop loss of Rs 560. The stock has risen by 35.48% in the last 12 months and by 36.38% so far this year. Its relative strength index is at 66.80.

As per Bloomberg data, 16 analysts cover the stock, with seven assigning a ‘buy’ rating, three a ‘hold,’ and six a ‘sell.’ The 12-month consensus target is Rs 446.20, offering an expected downside of 23.9%.

HCC

Parekh recommends purchasing the stock at Rs 38 with a target of Rs 42 and a stop loss at Rs 36. Over the past year, the stock has yielded 53.57% returns, and in the year-to-date period, it has gained 55.45%. Its relative strength index is currently at 36.55. The one analyst tracking the stock as per Bloomberg, recommends to ‘buy.’

IPCA Laboratories

Rajani advises buying the stock at Rs 1,639, targeting Rs 1,680 with a stop loss at Rs 1,610. The stock has moved 45.86% higher in the past 12 months and 46.67% year-to-date. The relative strength index is recorded at 61.75.

Bloomberg data indicates 21 analysts cover the stock, with 12 giving it a ‘buy,’ two a ‘hold,’ and seven a ‘sell.’ Analysts’ consensus for the next 12 months sets the target at Rs 1546.42, suggesting an downside of 5.3%.

Disclaimer: The views and opinions expressed by the investment advisers on NDTV Profit are of their own and not of NDTV Profit. NDTV Profit advises users to consult with their own financial or investment adviser before taking any investment decision. 

. Read more on Markets by NDTV Profit.Here are all the top ‘buy’ calls from analysts you need to know about on Monday.  Read MoreMarkets, Business, Notifications 

​NDTV Profit